CVC Capital Partners ("CVC") today announced that funds advised by CVC have finalised the sale of part of their stake in Jintian Pharmaceutical Group Ltd ("Jintian"), a leading pharmaceutical retailer and distributor in Northeast China, which is listed on the Hong Kong Stock Exchange.
Funds advised by CVC have sold 185,500,000 shares at the price of HK$3.29 per share, and retain a stake of 6.9% in the business.
CVC funds made an initial investment in Jintian in October 2011, acquiring a 24.2% stake. The company successfully completed its listing on the Hong Kong Stock Exchange in December 2013.
Francis Leung, Managing Partner and Chairman of Greater China for CVC, commented: "We are pleased that CVC funds invested and remain invested in Jintian. The recent sale of part of the CVC funds' investment in the business is in line with our usual process of managing CVC fund investments and has realised a solid return for our investors. CVC will continue to support the management of Jintian in executing its strategic objectives."
Amova Asset Management expands Asian and Regional footprint through full controlling stake in AHAM Capital
Asurion to acquire Domestic & General, establishing a global leader in technology and appliance care committed to excellence in customer service
Low Carbon secures landmark investment from CVC DIF to drive the next stage of growth
CVC DIF to divest 25% interest in Somerton Pipeline to Channel Infrastructure
CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally
CVC Secondary Partners expands into fast growing credit secondaries market
CVC Capital Partners plc appoints Catherine Keating as a Non-Executive Director